Nestle to Buy Aimmune Therapeutics

The food giant Nestle wants to acquire the biopharmaceutical company Aimmune Therapeutics, in which it currently holds a 25.6% stake

Trader 1

The food giant Nestle wants to acquire the biopharmaceutical company Aimmune Therapeutics, in which it currently holds a 25.6% stake. The group will launch a takeover bid for the Wall Street-listed company, offering $34.50 (31.18 Swiss francs) per share and valuing the company at $2.6 billion.

The proposed price implies a 170% premium to Friday's closing price of $12.60. The transaction will be financed with "available cash".
The acquisition will contribute to the organic growth in 2021, and to earnings by 2022-2023.

Nestle mainly wants to acquire Palforzia, a product recently approved in the United States, which is presented as the only product to help reduce the frequency and severity of peanut allergic reactions in children.

From a chartist’s point of view, the stock price is trading within a short term upward-sloping channel since April 2020 and remains supported by its rising 50DMA currently at 108.14CHF. Prices are nearing the former resistance at 113.2CHF. A short term consolidation move cannot be ruled out. As long as 105CHF is support, the bias remains bullish. A push above 113.2CHF would call for a new up leg towards 120CHF. Alternatively, a break below the channel support at 105CHF would call for a reversal down trend with 99.8CHF as target. 

Source: GAIN Capital, TradingView

More from Equities

Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.

Open an Account